LSD & Acid

Definium’s LSD Tablet Clears a Third Phase 3, With a Design Aimed at the Blinding Problem

Definium's DT120 met its primary endpoint in the Panorama trial. A low-dose arm was added to address functional unblinding, and a dose-response pattern emerged.

An Oral LSD Tablet Has Now Cleared Phase 3 Twice This Year. Here Is What Comes Next

Editor’s note (September 16, 2026): DT120 has since cleared a third Phase 3 trial. We covered the Panorama results and the low-dose arm designed to address unblinding. An oral LSD tablet has now cleared phase 3 twice in a single year. Definium Therapeutics reported that DT120 ODT met its primary endpoint in generalized anxiety disorder, […]

Why Some Psychedelic Sessions Turn Frightening. A New Brain Study Offers a Clue

Most people who take a psychedelic under clinical supervision come through the session well. Some do not. A 2026 Stanford study in the Proceedings of the National Academy of Sciences offers a partial explanation for that difference. The clue sits in an unexpected place, namely the direction brain signals travel. Do you work in the […]

Nearly 5 Million Veterans Have Tried Psychedelics, RAND Study Finds

Psychedelics are no longer a fringe topic among veterans. They are part of the lived experience of millions of those who serve in the military.

Definium’s Phase 3 LSD Drug Clears a Major Depression Test

Definium Therapeutics LSD based pill, DT120 ODT, reduced depression symptoms in a phase 3 trial of adults with major depressive disorder.

New Brain Scan Study Looks At Psychedelics And Emotional Processing

Brain scans are beginning to show a more detailed picture of how regular psychedelic users may process emotional threat. Single sessions may matter as much as habits, since one dose of psilocybin may leave lasting effects. A recent brain imaging study found that people who regularly use psychedelics outside clinical settings responded differently to emotional […]